Clinical trials
Epithelial Tumors, Malignant clinical trials
Below are recruiting epithelial tumors, malignant clinical trials, each written for real people, not researchers. We’re tracking 52 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05141474RecruitingEarly Phase 1
Personalized immune cell treatment for advanced cancers after failed therapy
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
BarcelonaAges 18 years+ - NCT05457595Recruiting
Re-irradiation for pelvic and groin cancer recurrences
This study tests giving radiation again to treat a cancer that has returned in the pelvic area (including the groin) when surgery isn’t a good option. It may help control the tumor while trying to protect nearby organs such as the small intestine.
Pavia, PvAges 18 years+ - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT02146170Recruiting
Blood and tissue collection study for several lung and chest cancers
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
Bethesda, MarylandAges 18 years+ - NCT07400263Recruiting
Testing a new imaging agent for epithelial tumors
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07691619RecruitingPhase 2
Shorter radiation after surgery for thymus cancer
This trial tests a shorter course of radiation therapy (hypofractionated) after surgery for people with Stage II or III thymoma or thymic cancer. The goal is to prevent the tumor from coming back.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07443020RecruitingPhase 1
Fast immune cells for fluid build-up from cancer
This trial tests a treatment using your own immune cells (T cells) to fight cancer that has spread to the lining of the lung and is causing fluid buildup. It may help if other standard treatments have stopped working.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06592417RecruitingPhase 1
Study of JSKN016 for advanced solid tumors
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
Fuzhou, FujianAges 18 years+ - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT05667948Recruiting
Testing targeted treatments for thymus cancer using tumor testing
This trial studies people with thymus (thymic) cancers that have been confirmed by tissue testing. It uses tumor “molecular” (biologic/genetic) test results to guide treatment options and see how well they work.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06311955RecruitingPhase 2
Carbon ion radiation for residual thymus tumor after surgery
This trial tests a type of radiation called carbon ion therapy for people with thymus cancer that was not completely removed during surgery. The goal is to see if this treatment can target the remaining tumor cells safely and effectively.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06692062Recruiting
Hypofractionated radiation for thymoma and thymic carcinoma
This trial tests a shorter course of radiation (hypofractionated radiotherapy) for people with thymoma or thymic carcinoma. It aims to see if fewer, larger doses of radiation are safe and effective for treating these tumors.
Changsha, HunanAges 18–75 - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+ - NCT06311968RecruitingPhase 2
Proton radiation after surgery for thymus tumors
This trial tests a type of precise radiation called proton therapy after surgery for thymus tumors. It may help reduce the chance of the tumor coming back while limiting side effects to nearby organs.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06464055RecruitingPhase 1/Phase 2
A study of GQ1010 for advanced solid tumors
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
BeijingAges 18 years+ - NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT07128914RecruitingPhase 1
Study of GO306 for advanced solid tumors
This trial tests a new drug called GO306 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have certain cancers like breast, bladder, colorectal, kidney, ovarian, or neuroendocrine tumors, and you have malignant ascites (fluid buildup in the belly) that needs treatment.
Hefei, AnhuiAges 18 years+ - NCT06576037RecruitingPhase 1
Study of CBP-1019 with chemo for advanced solid tumors
This trial tests a new drug called CBP-1019 combined with chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have a type of cancer that hasn't gotten better with other therapies.
Houston, TexasAges 18 years+ - NCT07266298RecruitingPhase 1
T-cell therapy for advanced solid tumors
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+
Hear when a new Epithelial Tumors, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for epithelial tumors, malignant?
- Yes. Clin2 currently lists 52 recruiting epithelial tumors, malignant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epithelial tumors, malignant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epithelial tumors, malignant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.